As expected, across all gliomas, the prevalence of IDH1/2-mutant gliomas decreased as patients became older, with only 75 out of 966 patients ≥65 years old having an IDH1/2-mutant astrocytoma or oligodendroglioma (Figure 5D-E). Here, IDH1 is linked to central nervous system cancer.